A global biotechnology leader specializing in rare diseases, immunology, and vaccines, CSL Limited operates plasma collection networks and develops life-saving therapies. The company's vertically integrated business model and strong R&D pipeline make it a key player in biopharmaceuticals. Investors monitor CSL for its steady growth in plasma-derived therapies and expansion into gene therapy markets.
4 members of Congress have disclosed 7 trades in CSL Limited (CSLLY), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 5 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-10 | Daniel Goldman | sell | $50K – $100K |
| 2023-02-27 | Daniel Goldman | buy | $15K – $50K |
| 2018-12-07 | Greg Gianforte | sell | $100K – $250K |
| 2018-11-30 | Josh Gottheimer | sell | $1K – $15K |
| 2018-11-29 | Josh Gottheimer | sell | $1K – $15K |
| 2017-05-30 | Josh Gottheimer | sell | $1K – $15K |
| 2017-04-19 | Francis Rooney | buy | $1K – $15K |